ArticleBMC neurology2025
Implications of coexisting neural antibodies with glial fibrillary acidic protein autoimmunity: a single center retrospective cohort study.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
background and purposeThis study aimed to elucidate the differences between patients with anti-glial fibrillary acidic protein (GFAP) antibodies who exhibited concurrent positivity for other neuro-antibodies and those who did not.
methodsHospitalised patients demonstrating anti-GFAP antibody positivity in cerebrospinal fluid (CSF) were retrospectively collected and followed up from March 2019 to July 2022. Data including clinical features, laboratory results, imaging findings, therapy, and prognosis were extracted from the medical record system.
resultsThirty-seven patients with positive anti-GFAP antibody in CSF were included. Ten patients exhibited concomitant other neuro-antibodies and were categorised as the "overlapping group". Compared to the non-overlapping group, the incidence of seizures was significantly higher in the overlapping syndrome group (50% vs. 3.7%, p = 0.003), and a similar trend was observed for status epilepticus (30% vs. 3.7%, p = 0.052). Encephalitis was more prevalent in the overlapping group (60.0%) than in the non-overlapping group (11.1%) (P = 0.005). Serum white blood cell and neutrophil counts were significantly higher in the overlapping group compared to the non-overlapping group (P = 0.037, P = 0.042, respectively). The overlapping group demonstrated a higher percentage of immunosuppressant usage and a longer hospital stay compared to the non-overlapping group. During the follow-up, two patients in the overlapping group expired, while all the patients in the non-overlapping group survived.
conclusionsPatients with anti-GFAP antibodies and concurrent other neuro-antibodies exhibited different clinical features compared to non-overlapping cases. We suggest that in the presence of coexisting neuronal surface antibodies, these specific neuro-antibodies were predominant in clinical manifestations and prognosis, rather than the anti-GFAP antibody, especially when in a relatively high titer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.